Management of HIV/AIDS Press Release

Title Picture
05/21/2018 - 08:51
Janssen Announces European Commission Approval of JULUCA (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-1
Johnson and Johnson's picture
Johnson and Johnson
05/21/2018 - 04:41
ViiV Healthcare receives EU marketing authorisation for Juluca (dolutegravir/rilpivirine), the first 2-drug regimen, once-daily, single-pill for the treatment of HIV
GlaxoSmithKline's picture
GlaxoSmithKline
05/17/2018 - 07:44
Nearly half of women with HIV lack support to manage menopause
University College London's picture
UniversityColle...
05/07/2018 - 06:27
NIH clinical trial to track outcomes of kidney transplantation from HIV-positive donors to HIV-positive recipients
National Institutes of Health's picture
NIH
04/18/2018 - 12:40
Top HIV Cure Research Team Refutes Major Recent Results on How to Identify HIV Persistence
Wistar Institute's picture
Wistar Institute
04/09/2018 - 11:54
Three Faculty Members Named Elite Medical and Biological Engineering Fellows
Northwestern University's picture
Northwestern Un...
03/28/2018 - 06:14
Mylan Introduces Symfi Triple Combo Once-Daily HIV Treatment in the U.S.
Mylan's picture
Mylan
03/23/2018 - 04:10
ViiV Healthcare gains CHMP positive opinion for Juluca (dolutegravir/rilpivirine) in Europe
GlaxoSmithKline's picture
GlaxoSmithKline
03/06/2018 - 16:02
Novel Population Council HIV and STI Prevention Research Presented at CROI, Worlds Preeminent HIV Research Meeting
Population Council's picture
Population Council
03/06/2018 - 10:18
FDA approves new HIV treatment for patients who have limited treatment options
Food and Drug Administration's picture
FDA
03/05/2018 - 13:02
ViiV Healthcare announces positive new dolutegravir data for the treatment of people living with HIV co-infected with tuberculosis
GlaxoSmithKline's picture
GlaxoSmithKline
03/05/2018 - 05:41
Broadly neutralizing antibody treatment may target viral reservoir in monkeys
National Institutes of Health's picture
NIH
03/02/2018 - 10:04
Mylan to Introduce Two New Cost-Saving HIV Combination Treatments in the U.S.
Mylan's picture
Mylan
03/01/2018 - 09:22
Merck to Present New Data from Studies of Investigational HIV Therapies Doravirine and MK-8591 at CROI 2018
Merck's picture
Merck
02/19/2018 - 13:01
Center for HIV Cure Research
Gladstone Institutes's picture
Gladstone Institutes
02/01/2018 - 07:04
Mylan Expands Access to HIV/AIDS Medicines with Launch of First Generic Sustiva Tablets
Mylan's picture
Mylan
01/24/2018 - 01:04
NIH begins large HIV treatment study in pregnant women
National Institutes of Health's picture
NIH
12/27/2017 - 08:06
Teva Announces Exclusive Launch of a Generic Version of Reyataz in the United States
Teva Pharmaceutical's picture
Teva Pharmaceutical
12/12/2017 - 21:19
Social stigma obstacle to successful treatment of children with HIV in Ethiopia
Lund University's picture
LundUniv
12/01/2017 - 14:00
Patients with HIV-Associated Lymphoma Can Safely Continue Anti-Retroviral Therapy During Chemotherapy
Fox Chase's picture
Fox Chase
12/01/2017 - 11:24
Ukraine: People co-infected with HIV to receive hepatitis C treatment in Mykolaiv region
Médecins Sans Frontières's picture
MSF
12/01/2017 - 10:09
Rising levels of HIV drug resistance
University College London's picture
UniversityColle...
11/29/2017 - 17:59
Merck Receives FDA Approval for ISENTRESS (raltegravir), in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in Newborns Weighing at Least 2 kg
Merck's picture
Merck
11/27/2017 - 11:32
ViiV Healthcare starts third phase III HIV treatment study investigating long-acting two-drug regimen of cabotegravir plus rilpivirine
GlaxoSmithKline's picture
GlaxoSmithKline
11/21/2017 - 15:23
FDA approves first two-drug regimen for certain patients with HIV
Food and Drug Administration's picture
FDA
11/21/2017 - 02:23
Juluca (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill - a complete regimen for the maintenance treatment of virologically suppressed HIV-1 infection
GlaxoSmithKline's picture
GlaxoSmithKline
11/20/2017 - 01:51
UA Collaboration Focuses Attention on Emergency HIV Patients
University of Arizona's picture
ArizonaUniv
10/27/2017 - 02:53
ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV
GlaxoSmithKline's picture
GlaxoSmithKline
10/20/2017 - 12:42
HIV Patients Can Control the Virus, but Theyre Still Hoping for a Cure
Gladstone Institutes's picture
Gladstone Institutes
10/17/2017 - 10:55
New Research Opens the Door to Functional Cure for HIV
Scripps Research's picture
Scripps Research
10/05/2017 - 12:40
Researchers create molecule that could kick and kill HIV
University of California Los Angeles's picture
UCLA
10/04/2017 - 15:18
Janssen Submits New Drug Application to U.S. Food and Drug Administration for the First Darunavir-Based Single Tablet Regimen for the Treatment of HIV-1
Johnson and Johnson's picture
Johnson and Johnson
09/28/2017 - 11:03
Indonesian prisoners with HIV getting aid from UIC researchers
University of Illinois's picture
UICUniv
09/20/2017 - 10:33
Study will examine role of resilience among African Americans living with HIV
Brown University's picture
BrownUniversity
08/07/2017 - 21:51
Mylan Launches Avonza in India
Mylan's picture
Mylan
08/07/2017 - 03:54
Mylan Receives Tentative Approval for "TLD" Under PEPFAR
Mylan's picture
Mylan
07/25/2017 - 09:48
ViiV Healthcare announces superior efficacy of dolutegravir versus lopinavir/ritonavir in second-line HIV treatment in resource-limited settings
GlaxoSmithKline's picture
GlaxoSmithKline
07/25/2017 - 09:05
Switching to a dolutegravir regimen from a boosted protease inhibitor regimen maintained viral suppression and improved lipid fractions in patients with HIV and high cardiovascular risk
GlaxoSmithKline's picture
GlaxoSmithKline
07/25/2017 - 05:56
Mercks Investigational NNRTI, Doravirine, Meets Primary Efficacy Endpoint of Non-Inferiority to Efavirenz, Both in Combination with Other Antiretroviral Agents, in Pivotal Phase 3 Trial for Treatment of HIV-1 Infection
Merck's picture
Merck
07/24/2017 - 05:24
Phase II study results showed comparable viral suppression rates at 96 weeks for a two-drug regimen of long-acting cabotegravir and rilpivirine and a three-drug regimen in patients with HIV
GlaxoSmithKline's picture
GlaxoSmithKline
07/24/2017 - 05:22
Child living with HIV maintains remission without drugs since 2008
National Institutes of Health's picture
NIH
07/24/2017 - 03:38
Merck Announces Week 96 Results from ONCEMRK, A Study Evaluating Once-Daily ISENTRESS HD (raltegravir), in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in Appropriate Patients
Merck's picture
Merck
07/20/2017 - 12:35
ViiV Healthcare shares data from its innovative portfolio with HIV community at IAS 2017
GlaxoSmithKline's picture
GlaxoSmithKline
07/20/2017 - 02:48
Low-cost drugs package saves lives of people starting HIV treatment late
University College London's picture
UniversityColle...
07/13/2017 - 13:02
- First in-human, Phase 1/2a data from APPROACH preventive HIV-1 vaccine clinical trial to be featured in oral presentation and included in official IAS press program -
Johnson and Johnson's picture
Johnson and Johnson
07/06/2017 - 11:18
Merck to Present New Data from Clinical Trials Evaluating ISENTRESS HD (raltegravir) and Investigational HIV Therapies Doravirine and MK-8591 at IAS 2017
Merck's picture
Merck
06/26/2017 - 16:33
Integrated medical records can reduce disparities between blacks and whites in HIV care
University of California Los Angeles's picture
UCLA
06/21/2017 - 20:26
Illuminating the developing worlds invisible consumers
Massachusetts Institute of Technology's picture
MIT
06/21/2017 - 18:35
HIV-positive women with cytomegalovirus likelier to pass virus that causes AIDS to infant
University of California Los Angeles's picture
UCLA
06/01/2017 - 15:34
Janssen Announces Submissions in Europe and US for Single- Tablet Regimen of Dolutegravir plus Rilpivirine - the First Two-Drug HIV Maintenance Treatment
Johnson and Johnson's picture
Johnson and Johnson
06/01/2017 - 05:30
ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicines
GlaxoSmithKline's picture
GlaxoSmithKline
05/30/2017 - 08:00
Reservoirs of Latent HIV Can Grow Despite Effective Therapy, Study Shows
Johns Hopkins Health System's picture
Johns Hopkins H...
05/30/2017 - 03:46
Merck Receives FDA Approval of ISENTRESS HD (raltegravir), a New Once-Daily Option, in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in Appropriate Patients
Merck's picture
Merck
05/29/2017 - 08:43
Toward an HIV Cure: Pitt Team Develops Test to Detect Hidden Virus
University of Pittsburgh Medical Center's picture
UPMC
05/25/2017 - 08:04
HIV patients sticking with therapy longer, Medicaid data show
Brown University's picture
BrownUniversity
05/19/2017 - 06:02
Merck Receives CHMP Positive Opinion Recommending Approval of ISENTRESS (raltegravir) 600 mg in the European Union
Merck's picture
Merck
05/18/2017 - 08:20
NIH statement on HIV Vaccine Awareness Day - 2017
National Institutes of Health's picture
NIH
05/17/2017 - 14:54
UIC nurse researcher receives Fulbright to study in Rwanda
University of Illinois's picture
UICUniv
05/10/2017 - 22:59
Life expectancy for people with HIV has increased by 10 years in the US and Europe since introduction of antiretroviral therapy
 University of Bristol's picture
University of B...
05/10/2017 - 12:17
Study Reveals a New Method to Address a Major Barrier to Eradicating HIV
Gladstone Institutes's picture
Gladstone Institutes